Jake Holdreith

Jake Holdreith

April 23, 2013 | Inside Counsel

IP: India, generics and the impact of Novartis’ failed Gleevec claims

India has earned its reputation as the worlds pharmacy because it suppliesprimarily in the form of genericsmuch of the affordable medicine needed by countries in the developing world.

By Jake Holdreith, Bryan J. Vogel

6 minute read

April 09, 2013 | Inside Counsel

IP: The failure of venue and joinder reform in patent litigation

Until recently, a patent plaintiff had its choice of bringing suit in any forum in which an accused product was soldin practice, usually any court in the country.

By Jake Holdreith

16 minute read

March 26, 2013 | Inside Counsel

IP: Why do patent cases cost so much to get through trial?

It is no secret that patent cases are some of the most expensive cases to get through trial.

By Jake Holdreith

7 minute read

March 12, 2013 | Inside Counsel

IP: Navigating the divide

Academic and noncommercial basic research has always been an engine for innovation, particularly in the areas of medicine and drugs.

By Jake Holdreith, Jamie Kurtz

12 minute read

February 26, 2013 | Inside Counsel

IP: Patent Office trials—A good way to deal with bad patents?

Even if theyve never faced a patent infringement lawsuit filed in federal district court, virtually every inside counsel has had to deal with a letter containing notice of alleged patent infringement.

By Jake Holdreith, Cy Morton

12 minute read

February 12, 2013 | Inside Counsel

IP: 5 things to discuss at your first case meeting with outside trial counsel

As a trial lawyer who has conducted many complex intellectual property case kickoffs between inside and outside counsel teams, Ive discovered that covering five key questions during that first meeting provides a dependable format for success.

By Jake Holdreith

12 minute read